Immunological and molecular Characterization of lung tumour

• Conditions: C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00005376
• Lead Sponsor: niversitätsklinikum ErlangenAnästhesieAbteilung Molekulare Pneumologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-13
• Results First Posted: 2014-12-10
• Study Completion: 2022-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 153

Inclusion Criteria

Further inclusion criteria
Patients with suspicion of/ or diagnosed lung tumor with medical indication for

1) VATS (video-assisted thoracoscopic surgery) or open surgical procedure on the lung and
2) taking blood and/or
3) performance of a bronchoscopy with bronchoalveolar lavage

Exclusion Criteria

- limited coagulation (Quick<50%, PTT>50s, thrombocytes<100000/µl)
- limited kidney function (creatinine Kreatinin > 1,5mg/dl)
- pregnancy
- nursing period
- limited or non-existent compliance ability
- amyloidosis (SSA), family-related polyneuropathy (FAP) and family-related cardiomyopathy
- other severe diseases

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
• Identification of targeted immunotherapy for patients with lung cancer<br>• recurrence rate and survival (within one year)<br>

Secondary Outcome Measures

Name	Time	Method
• Identification of immunological and clinical parameters for early diagnosis/ prognosis of patients with lung cancer <br>• Characterisation of the relation between nutritional status and immun status in patients with lung cancer<br><br>Surrogate-Markers<br>• CD4+ T-Zellen, CD8+T-Zellen, TGFß, IL 2, IL 10, IL 12, Transthyretin level in serum, Tbet, T regulatory cells, etc. <br>